Saxagliptin misses efficacy mark in trial

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

Saxagliptin failed to meet its primary efficacy endpoint in a clinical trial designed to assess whether the drug reduced the risk of cardiovascular events when used alone or added to other diabetes medications.

Results of Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) were announced by its sponsors, Bristol-Myers Squibb and AstraZeneca. The companies reported that they are analyzing the data and plan to present results Sept. 2 at the European Society of Cardiology Congress in Amsterdam.

SAVOR-TIMI-53 is a multicenter, randomized, double-blind, placebo-controlled trial that aimed to enroll 16,500 patients with type 2 diabetes who were at high risk of a cardiovascular event due to a history of established cardiovascular disease or multiple risk factors. The study’s primary efficacy and safety outcomes were the composite endpoint of cardiovascular death, nonfatal MI or nonfatal ischemic stroke.

Secondary outcome measures included the composite endpoint of cardiovascular death, nonfatal MI, nonfatal ischemic stroke, hospitalization for heart failure, unstable angina pectoris or coronary revascularization; or any documented death.

Saxagliptin (Onglyza) met the primary safety measure of noninferiority compared with placebo but it did not meet the primary efficacy measure of superiority.

Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was approved by the FDA in 2009. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Candace Stuart, Contributor

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."